壳聚糖膜在保留神经根治性前列腺切除术后促进性功能早期恢复
该比较研究评估壳聚糖膜(ChiMe)应用于保留神经机器人辅助根治性前列腺切除术(NS-RARP)后神经血管束对1年性功能恢复率的影响。ChiMe组136例,对照组334例。结果显示ChiMe组术后1个月(36.76% vs 25.88%,P=0.02)和2个月(52.2% vs 39.22%,P=0.01)性功能恢复率显著提高,但2个月后无显著差异。
要点
- 壳聚糖膜可提高NS-RARP术后1-2个月性功能恢复率。
- 保留神经数量是影响性功能恢复的独立因素。
- 2个月后壳聚糖膜获益无统计学显著性。
核心结论
- 在双侧或单侧完全保留神经的NS-RARP中,神经血管束应用ChiMe可提高术后1个月和2个月的性功能恢复率。
- 即使未行完全保留神经,应用ChiMe也呈现更高更短性功能恢复时间的有利趋势。
研究设计与样本
- 前瞻性II期初步研究(ChiMe组)与同期对照比较:ChiMe组136例于2015年7月至2016年9月入组,对照组334例自2015年1月起未应用ChiMe。
- 根据神经保留程度分为A组(单侧或双侧完全保留神经,183例)和B组(未完全保留神经,287例)。
主要发现
- 总体比较:ChiMe组 vs 对照组术后1个月性功能恢复率36.76% vs 25.88%(P=0.02),2个月52.2% vs 39.22%(P=0.01)。
- A组中ChiMe组 vs 对照组log-rank检验P=0.02,术后1个月和2个月P分别为0.02和0.01。
- 影响性功能恢复的仅有因素为保留神经数量(A组 vs B组)和是否应用ChiMe。
临床怎么用
- 对于接受NS-RARP的患者,可考虑在保留的神经血管束上应用壳聚糖膜以促进术后早期性功能恢复。
局限性
- ChiMe组为II期初步研究,样本量有限。
- 为非随机对照比较研究。
- 随访1年,2个月后获益无统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the 1-year efficacy of chitosan membrane (ChiMe) application on the neurovascular bundles (NVBs) after nerve-sparing (NS) robot-assisted radical prostatectomy (RARP) in potency recovery rate. To compare the results with those of a contemporary cohort of patients who did not benefit from chitosan use. PATIENTS AND METHODS: Patients in the ChiMe group were enrolled at our institution from July 2015 to September 2016 in a preliminary phase II study. All of them underwent NS-RARP with ChiMe applied on the NVBs and were followed over time to complete a 1-year follow-up. The control group was composed of patients who underwent NS-RARP at our institution without the application of ChiMe from January 2015. The patients were further classified into two groups based on the amount of nerves spared: Group A, comprised patients who underwent a monolateral or bilateral full NS; Group B, comprised patients in which a full NS was not performed. The demographics, peri- and postoperative data, and complications were recorded and compared. Potency recovery was recorded for Group A vs Group B in both the ChiMe and the control groups. RESULTS: In all, 136 patients were enrolled in the ChiMe group and 334 patients in the control group. There were no differences between groups in terms of baseline variables. Based on the amount of nerves preserved, 183 patients were included in Group A and 287 in Group B. Odds ratios at different time points showed that the only two factors influencing potency recovery were the amount of nerves preserved (Group A vs Group B) and the application or not of ChiMe on the NVBs spared. Comparing the ChiMe vs control groups at different time points, we found a statistically significant improvement in the potency recovery rate in the ChiMe group at 1 month (36.76% vs 25.88%; P = 0.02) and 2 months (52.2% vs 39.22%; P = 0.01) after surgery, showing a favourable trend at every time point of the entire follow-up period, even if not significant after the second postoperative month. In Group A, the log-rank test showed a statistically significant difference between the ChiMe vs control groups (P = 0.02), in particular at 1 and 2 months after surgery (P = 0.02 and P = 0.01, respectively). CONCLUSION: The application of ChiMe on the NVBs resulted in a higher potency recovery rate at 1 and 2 months after a bilateral or monolateral full NS-RARP. A trend of a higher and shorter potency recovery rate showed it to be favourable to use ChiMe, even in the cohort of patients who did not undergo a full NS procedure.
引用
- Porpiglia F, Manfredi M, Checcucci E, et al. Use of chitosan membranes after nerve-sparing radical prostatectomy improves early recovery of sexual potency: results of a comparative study. BJU Int. 2018. PMID: 30303604. doi:10.1111/bju.14583
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。